GamaMabs Pharma, a French biotechnology company focused on cancer treatment, has raised €15m for Edmond de Rothschild Investment Partners (EdRip) and its previous backers.
US-based parent company Omnimax International sold the business to the Netherlands-based GP
Fund will target companies with revenues of at least €5m, operating in a wide range of innovative sectors
GP intends to support Sicura by boosting its growth both organically and via strategic acquisitions
WFSC joins a group of existing investors that committed to the round in September 2019